Quibim
Transforming imaging data into actionable predictions
About Quibim
Founded in 2015 in Valencia, Spain, by Angel Alberich-Bayarri and Luis Marti-Bonmati, Quibim is a healthtech company that applies artificial intelligence to medical imaging. Its name is short for Quantitative Imaging Biomarkers in Medicine. The company began as a spin-off of La Fe Health Research Institute in Valencia.
Quibim’s platform, QUIBIM Precision, extracts and quantifies disease-specific biomarkers from MRI, CT and PET scans, turning images into actionable predictions for oncology, neurology and immunology. Its product line includes QP-Prostate and QP-Brain, both cleared by the FDA as medical devices, alongside QP-Liver and AI-QUAL, an automated tool for prostate MRI image quality assessment. The company reports more than 170 installations worldwide and works with over 150 hospitals, with pharmaceutical clients including Merck KGaA and Novartis.
Quibim is expanding its presence in the United States as it works with pharmaceutical leaders and healthcare providers to unlock the power of imaging in diagnostics. Its partners include Philips, which integrated Quibim’s prostate solution into its MRI scanners, along with Aidoc and NVIDIA MONAI. The company is headquartered in Valencia with offices in New York, Cambridge, Madrid and Barcelona.
Founders
Funding History
Frequently Asked Questions
What does Quibim do?
Quibim designs AI tools that unlock imaging data to improve patient outcomes. Its QUIBIM Precision platform extracts quantitative imaging biomarkers from MRI, CT and PET scans, turning them into actionable predictions for life sciences companies and healthcare providers in areas such as oncology, neurology and immunology.
Who founded Quibim?
Quibim was founded in 2015 in Valencia, Spain, by Angel Alberich-Bayarri and Professor Luis Marti-Bonmati. It began as a spin-off of La Fe Health Research Institute.
How much funding has Quibim raised?
Quibim has raised over $60 million in total. This includes an 8 million euro seed round in July 2020 and a $50 million Series A round in January 2025, co-led by Asabys Partners and Buenavista Equity Partners.
Are Quibim's products FDA cleared?
Yes. Quibim's QP-Prostate and QP-Brain products have received FDA 510(k) clearance as medical devices for aiding prostate cancer detection and neurological assessment.
What is QUIBIM Precision?
QUIBIM Precision is the company's proprietary platform for medical image post-processing. It extracts and quantifies disease-specific biomarkers from medical images with high accuracy, and is used by more than 150 hospitals and 11 clinical trials around the world.
